申请人:Metabolex Inc.
                            
                            
                                公开号:EP2514745A1
                            
                            
                                公开(公告)日:2012-10-24
                            
                            
GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
                            提供了 GPR120 激动剂。这些化合物可用于治疗代谢性疾病,包括 II 型糖尿病和与血糖控制不良有关的疾病。